Stockreport

FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease [Yahoo! Finance]

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. In December 2023, the FDA approved Fabhalta a [Read more]